14/09/2026
MASLD affects roughly 1 in 3 American adults — but it is still too often dismissed as “just fatty liver.” Learn how the disease can progress from steatosis to fibrosis and cirrhosis, how to use non-invasive screening and risk stratification, and what is changing in treatment.
Register for the New England Health Summit before Early Bird rates end October 1.
Learn more:https://nhnpa.my.canva.site/